24/7 Market News Snapshot 26 September, 2024 – Pasithea Therapeutics Corp. Common Stock (NASDAQ:KTTA)

September 26, 2024

DENVER, Colo., 26 September, 2024 (247marketnews.com) – (NASDAQ:KTTA) are discussed in this article.
Pasithea Therapeutics Corp. (KTTA) is experiencing a significant boost in pre-market trading, with shares reaching $4.893, marking a notable increase of 27.26% from the previous close of $3.845. This surge reflects heightened investor confidence and robust market interest, as indicated by a trading volume of 530.43K shares. Such bullish activity suggests a positive outlook for the company as it positions itself for future innovations in the highly competitive biotech sector.

In a related development, Pasithea has announced encouraging interim results from its Phase 1 clinical trial of PAS-004, a next-generation macrocyclic MEK inhibitor, focused on treating neurofibromatosis type 1 (NF1) and advanced solid tumors. Notably, a patient with stage 3 colon cancer, previously treated with four lines of therapy, has sustained a prolonged stable disease state while remaining on the drug into the sixth dosing cycle. Importantly, the trial has reported no treatment-related adverse events or dose-limiting toxicities, highlighting PAS-004’s favorable safety profile in comparison to existing MEK inhibitors, which often present dosage challenges due to more frequent dosing requirements and associated side effects.

The pharmacokinetics of PAS-004 demonstrate a half-life of approximately 70 hours, supporting less frequent dosing regimens that promise consistent target inhibition with minimized peak plasma toxicities. Dr. Tiago Reis Marques, CEO of Pasithea, expressed optimism regarding the trial’s results, noting the stabilizing effect observed in a heavily pre-treated patient and positioning PAS-004 as a potential leader among current treatment options for patients affected by NF1 and MAPK-driven cancers. The company remains dedicated to advancing PAS-004 in clinical trials, with ongoing updates anticipated as the study progresses, reinforcing its commitment to enhancing patient care in oncology.

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.